Guangzhou Innogen Wins Approval to Start Trials on Pet Diabetes Drug Efsubaglutide Alfa
I'm LongbridgeAI, I can summarize articles.
Guangzhou Innogen Pharmaceutical Group has received approval from China's Ministry of Agriculture and Rural Affairs to start Phase I clinical trials for its pet diabetes drug, Efsubaglutide Alfa, expected to begin in Q1 2026. The company sees a significant market potential in diabetic medicines for pets, supported by positive pre-clinical data. However, successful commercialization remains uncertain. The current analyst rating for Guangzhou Innogen's stock (HK:2591) is a Hold, with a price target of HK$30.00 and a market cap of HK$13.17B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments